2026 ICD-10-CM Diagnosis Code T37.95XAAdverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter
T37.95XA is a billable ICD-10-CM diagnosis code for adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. The code is not accepted as a principal diagnosis by the Medicare Code Editor. Coders also document this condition as allergic reaction caused by antiinfective agent. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Adverse effects of drugs and medicaments, initial encounter.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for T37.95XA.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Allergic reaction caused by antiinfective agent
- Antifungal drug adverse reaction
- Anti-infectives adverse reaction
- Contact dermatitis caused by scabicide
- Fetal disorder caused by anti-infective agent transmitted via placenta
Coding GuidelinesGuidance
When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics (T37). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Acriflavine
3,6-diamino-10-methylacridinium chloride mixt. with 3,6-acridinediamine. fluorescent dye used as a local antiseptic and also as a biological stain. it intercalates into nucleic acids thereby inhibiting bacterial and viral replication.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
| Substance | Accidental | Self-harm | Assault | Undetermined | Adverse Effect | Underdosing |
|---|---|---|---|---|---|---|
| Acriflavine | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::anthelmintic | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antibiotics | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antibiotics::specified NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antimalarial | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antimycobacterial NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antimycobacterial NEC::antibiotics | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antiprotozoal NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antiprotozoal NEC::blood | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::antiviral | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::arsenical | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::bismuth, local | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::ENT | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::eye NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::heavy metals NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::local NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::local NEC::specified NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::mixed | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::ophthalmic preparation | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Anti-infective NEC::topical NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Antiparasitic drug (systemic) | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Antiparasitic drug (systemic)::local | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Antiparasitic drug (systemic)::specified NEC | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Ethoxazene | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Furadantin | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Furoxone | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Nifuraldezone | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
| Serenium (hydrochloride) | T37.91 | T37.92 | T37.93 | T37.94 | T37.95 | T37.96 |
Patient EducationClinical
Drug Reactions
Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.
The full article covers:
- What is a drug interaction?
- What are side effects?
- What are drug allergies?
- How can I stay safe when taking medicines?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T37.95XA to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T37.95XAOverview
Is T37.95XA a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T37.95XA mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for adverse effect of unspecified systemic anti-infective and antiparasitic, such as an emergency visit or first evaluation.
What MS-DRG does T37.95XA group to?
On inpatient claims, adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter maps to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.
Can T37.95XA be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
What is the ICD-9 equivalent of T37.95XA?
Under the General Equivalence Mappings, adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter converts to ICD-9-CM 995.29 (adv eff med/biol NEC/NOS) and E931.9 (adv eff antinfct NEC/NOS). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
